First-trimester screening: Lessons from clinical trials and implementation

Current Opinion in Obstetrics and Gynecology

Volumn 18, Issue 2, 2006, Pages 152-155

  Koos, Brian J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRIOL; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

AMNIOCENTESIS; EDITORIAL; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; RISK ASSESSMENT; TRISOMY 21;

ADULT; AMNIOCENTESIS; BIOLOGICAL MARKERS; DOWN SYNDROME; FEMALE; HUMANS; MASS SCREENING; NEURAL TUBE DEFECTS; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; ULTRASONOGRAPHY, PRENATAL;

EID: 33646517097     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000192966.29449.01     Document Type: Editorial

References (32)

1. Bindra R, Heath V, Liao A, et al. One-step clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15,030 pregnancies. Ultrasound Obstet Gynecol 2002; 20:219-225.
2. Simpson JL. Choosing the best prenatal screening protocol. N Engl J Med 2005; 353:2068-2070.
3. Merkatz IR, Nitowsky HM, Macri JN, et al. An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984; 148:886-894.
4. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987; 7:623-630.
5. Canick JA, Knight GJ, Palomaki GE, et al. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988; 95:330-333.
6. Haddow JE, Palomaki GE, Knight GJ, et al. Prenatal screening for Down's syndrome with the use of maternal serum markers. N Engl J Med 1992; 327:588-593.
7. Phillips OP, Elias S, Shulman LP, et al. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol 1992; 80:353-358.
8. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353:2001-2011.
9. Wald NJ, Kennard A, Hackshaw S, et al. Antenatal screening for Down's syndrome. J Med Screen 1997; 4:181-246.
10. Krantz DA, Larsen JW, Buchanan PD, Macri JN. First-trimester Down syndrome screening: Free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Am J Obstet Gynecol 1996; 174:612-616.
11. Nicolaides KH, Azar G, Byrne D, et al. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. Br Med J 1992; 304:867-869.
12. Snijders RJM, Noble P, Sebire N, et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998; 352:343-346.
13. Krantz DA, Hallahan TW, Orlandi F, et al. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000; 96:207-213.
14. Avgidou K, Papageorghiou A, Bindra R, et al. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 2005; 192:1761-1767.
15. Nicholaides KH, Spencer K, Avgidou K, et al. Multicenter study of first-trimester screening for trisomy 21 in 75,821 pregnancies: results and estimation of the potential impact of individual risk-oriented two-stage first-trimeste screening. Ultrasound Obstet Gynecol 2005; 25:221-226.
16. Wøjdemann KR, Shalmi AC, Christiansen M, et al. Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women. Ultrasound Obstet Gynecol 2005; 25:227-233.
17. Perni SC, Predanic M, Kalish RB, et al. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Am J Obstet Gynecol (in press).
18. Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine, and Ultrasound Screening Study (SURUSS). J Med Screen 2003; 10:56-104.
19. Wapner R, Thom E, Simpson JL, et al. for the First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. N Engl J Med 2003; 349:1405-1413.
20. Orlandi F, Rossi C, Orlandi E, et al. First-trimester screening for trisomy-21 using a simplified method to assess the presence or absence of the fetal nasal bone. Am J Obstet Gynecol 2005; 192:1107-1111.
21. Snijders R, Nicolaides K. First trimester diagnosis of chromosomal defects. In: Nicolaides KH, editor. The 11-13+6 Weeks Scan. London: Fetal Medicine Foundation; 2004. pp. 7-44.
22. Greene N. First-trimester sonographic screening for Down syndrome (Letter to the editor). Obstet Gynecol 2004; 103:1000.
23. Sharma G, Gold HT, Chernevak FA, et al. Patient preference regarding first-trimester aneuploidy risk assessment. Am J Obstet Gynecol 2005; 193:1429-1436.
24. Nicolaides KH. First-trimester screening for chromosomal abnormalities. Semin Perinataol 2005; 20:190-194.
25. Spencer K, Bindra R, Nix ABJ, et al. Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester? Ultrasound Obstet Gynecol 2003; 22:142-148.
26. Malone FD. Nuchal translucency-based Down syndrome screening: barriers to implementation. Semin Perinatol 2005; 29:272-276.
27. Malone FD, M'Alton ME. First-trimester sonographic screening for Down syndrome. Obstet Gynecol 2003; 102:1066-1079.
28. Centini G, Rosignoli L, Scarinci R, et al. Re-evaluation of risk for Down syndrome by means of the combined test in pregnant women of 35 years or more. Prenat Diagn 2005; 25:133-136.
29. Platt LD, Greene N, Johnson A, et al. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 2004; 104:661-666.
30. Wright DE, Bradbury I, Benn P, et al. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 2004; 24:762-766.
31. Cuckle H, Benn P, Wright D. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol 2005; 29:252-257.
32. New England Regional Genetics Group Prenatal Collaborative Study of Down Syndrome Screening. Combining maternal serum α-fetoprotein measurements and age to screen for Down syndrome in pregnant women under age 35. Am J Obstet Gynecol 1989; 160:575-581.